Replies to post #155545 on Cytodyn Inc (CYDY)

[Hog Killer]

Kmax, it was age adjusted as a secondary endpoint. The 82% reduction was for paitients on ECMO

Here it is since you asked...

14 Day Mortality Endpoint

This was a secondary endpoint in the Statistical Analysis Plan filed with the FDA. The significance is that per the FDA guidelines CytoDyn may be able to move forward with full approval because the clinical trial did in fact meet a mortality endpoint that was statistically relevant. In critical patients with invasive mechanical ventilation (IMV) or ECMO following the standard of care the study revealed an 82% reduction in mortality at day 14. The result was statistically significant with a p=.0233. It’s staggering to think that patients that got leronlimab were 5 times more likely to be alive on day 14 versus the placebo. It’s also difficult to imagine that the FDA will be slow to act given this record setting data. Being alive is one criteria, but returning to your baseline after sickness is another powerful indicator that can help get people out of the hospital faster to free up beds in a pandemic. The 7-point ordinal scale measures a patient’s overall symptoms and is looking for some sort of clinical improvement. Leronlimab improved the OS by 400% with a p=.021.

[Leronlimab4DaWin]

they did not disclose yet another subgroup-in-a-subgroup data-mining performed (without correcting the p-values for data mining of course!!!)

Duh! Can you literally believe anything these scam artists say? Where is the uplist? What about Mexico? What about UK trial sites? What about EUA? Where are the CD10 data? Where is the S-3? Where is Fife? Did Nader say he won the self-enrichment lawsuits?